Goldman Sachs’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-1,158
| Closed | -$649K | – | 6086 |
|
|
2020
Q4 | $649K | Hold |
1,158
| – | – | ﹤0.01% | 4457 |
|
|
2020
Q3 | $809K | Hold |
1,158
| – | – | ﹤0.01% | 4219 |
|
|
2020
Q2 | $916K | Hold |
1,158
| – | – | ﹤0.01% | 4014 |
|
|
2020
Q1 | $689K | Hold |
1,158
| – | – | ﹤0.01% | 4009 |
|
|
2019
Q4 | $1.32M | Buy |
+1,158
| New | +$1.26M | ﹤0.01% | 3941 |
|
|
2019
Q2 | – | Sell |
-533
| Closed | -$1.09M | – | 5138 |
|
|
2019
Q1 | $1.09M | Sell |
533
-3,983
| -88% | -$7.01M | ﹤0.01% | 4010 |
|
|
2018
Q4 | $5.8M | Buy |
+4,516
| New | +$6.93M | ﹤0.01% | 2749 |
|
|
2017
Q4 | – | Sell |
-3,088
| Closed | -$5.49M | – | 6352 |
|
|
2017
Q3 | $5.49M | Buy |
+3,088
| New | +$4.31M | ﹤0.01% | 3055 |
|
|
2016
Q4 | – | Sell |
-7,334
| Closed | -$6.44M | – | 6899 |
|
|
2016
Q3 | $6.44M | Buy |
7,334
+6,948
| +1,800% | +$5.03M | ﹤0.01% | 2829 |
|
|
2016
Q2 | $216K | Buy |
+386
| New | +$219K | ﹤0.01% | 5635 |
|
|
2015
Q4 | – | Sell |
-4,462
| Closed | -$4.95M | – | 7143 |
|
|
2015
Q3 | $4.95M | Buy |
4,462
+2,918
| +189% | +$5.32M | ﹤0.01% | 2893 |
|
|
2015
Q2 | $3.37M | Buy |
+1,544
| New | +$3.15M | ﹤0.01% | 3322 |
|
|
2015
Q1 | – | Sell |
-3,860
| Closed | -$4.59M | – | 7080 |
|
|
2014
Q4 | $4.59M | Hold |
3,860
| – | – | ﹤0.01% | 3078 |
|
|
2014
Q3 | $1.79M | Buy |
+3,860
| New | +$1.78M | ﹤0.01% | 4043 |
|
Other funds holding BLUE
Goldman Sachs's BLUE Position: Q2 2025 in Review
Goldman Sachs sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 64,950 shares — an estimated $317K sold.
Goldman Sachs first reported a position in BLUE in Q3 2013 and held it in 46 quarters. The position peaked at $130M in Q2 2018. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.
- Goldman Sachs reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
- Goldman Sachs sold 64,950 bluebird bio shares in Q2 2025, an estimated $317K.
- Goldman Sachs first reported a position in bluebird bio in Q3 2013 and held it in 46 quarters.
- Goldman Sachs's bluebird bio position peaked at $130M in Q2 2018.
- 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.
Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.